Thu, May 8, 9:06 PM (41 days ago)
### MaxCyte, Inc. (MXCT) Q1 2025 Financial Summary **Revenue and Profit Margins:** - **Revenue:** $10.4 million, down 8% from $11.3 million in Q1 2024. - **Gross Profit:** $8.9 million, down 11% from $9.9 million in Q1 2024. - **Gross Margin:** 86%, down from 88% in Q1 2024. - **Operating Loss:** $12.3 million, slightly higher than $12.3 million in Q1 2024. - **Net Loss:** $10.3 million, up from $9.5 million in Q1 2024. **Cash Flow:** - **Net Cash Used in Operating Activities:** $14.4 million, up from $10.6 million in Q1 2024. - **Net Cash Provided by Investing Activities:** $9.5 million, a significant improvement from a use of $14.4 million in Q1 2024. - **Net Cash Provided by Financing Activities:** $0.4 million, down from $0.7 million in Q1 2024. **Earnings Changes:** - **Basic and Diluted Net Loss per Share:** $0.10, up from $0.09 in Q1 2024. **Quarterly Performance Discussion:** - **Revenue Decline:** Driven by a decrease in program-related revenue and instrument revenue, offset by an increase in PA revenue. - **Operating Expenses:** Research and development expenses decreased by 12%, while sales and marketing expenses decreased by 23%. General and administrative expenses increased by 20%. - **Cash Flow:** Improved investing activities offset by increased operating cash outflows. **Trends and Uncertainties:** - **Market Conditions:** The company faces competitive pressures and market uncertainties. - **Operational Impact:** Continued investment in research and development, sales, and marketing to drive future growth. - **Future Operations:** Expects to continue incurring net losses as it expands its business through growing sales and marketing efforts, continued research and development, and product development. **Future Outlook:** - **Revenue Growth:** Anticipates increased revenue from growing customer base and market expansion. - **Operational Efficiency:** Focus on cost management and operational efficiency to mitigate losses. - **Strategic Initiatives:** Continued investment in strategic acquisitions and partnerships to enhance market position. **Key Financial Metrics:** - **Total Assets:** $230 million, down from $239.5 million in Q1 2024. - **Total Liabilities:** $30.5 million, down from $33.2 million in Q1 2024. - **Stockholders' Equity:** $199.4 million, down from $206.3 million in Q1 2024. **Conclusion:** MaxCyte, Inc. faced revenue declines and increased operating losses in Q1 2025, driven by market conditions and strategic investments. The company is focused on operational efficiency and strategic initiatives to drive future growth and mitigate losses.